• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Pneumagen raises £8 million for Phase 2 trial of Neumafil nasal spray in COPD patients

Pneumagen said that it has closed an £8 million funding round, with proceeds going to support Phase 2 development of the company’s Neumifil multivalent carbohydrate binding module (mCBM) nasal spray, including a Phase 2b trial in COPD patients experiencing exacerbations caused by viral infection that is expected to be initiated in 2024.

The company announced in January 2022 that it had closed a £3.8 million funding round to support Phase 2 development and manufacturing of Neumifil. In May of that year, the company announced that a Phase 1 trial had demonstrated that the nasal spray was well tolerated, with no dose limiting toxicity. Pneumagen initiated a Phase 2a challenge study of Neumifil against influenza in August 2022 and now says that it expects to have initial results from that trial soon.

Pneumagen CEO Douglas Thomson commented, “We are very pleased to announce this funding from our existing and new investors. This financing speaks to their confidence in our strategy and the significant progress we have made.”

Read the Pneumagen press release.

Share

published on June 1, 2023

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    © 2025 OINDPnews